Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | ALK |
Variant | G1202X |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | ALK G1202X indicates any ALK missense mutation that results in replacement of the glycine (G) at amino acid 1202 by a different amino acid. |
Associated Drug Resistance | |
Category Variants Paths |
ALK mutant ALK G1202X |
Transcript | NM_004304.5 |
gDNA | chr2:g.29220745_29220747 |
cDNA | c.3604_3606 |
Protein | p.G1202 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_004304.5 | chr2:g.29220745_29220747 | c.3604_3606 | p.G1202 | RefSeq | GRCh38/hg38 |
NM_004304.4 | chr2:g.29220745_29220747 | c.3604_3606 | p.G1202 | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03737994 | Phase II | Cisplatin + Lorlatinib Carboplatin + Lorlatinib Ceritinib Alectinib + Cisplatin Alectinib + Carboplatin Ceritinib + Cisplatin Pemetrexed Disodium Carboplatin + Ceritinib Cisplatin + Ensartinib Carboplatin + Ensartinib Brigatinib + Cisplatin Brigatinib Alectinib Brigatinib + Carboplatin Ensartinib Cisplatin + Pemetrexed Disodium Crizotinib Carboplatin + Pemetrexed Disodium Lorlatinib | Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |